Clinical Trial Update: A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a new formulation of risankizumab for safety and efficacy in moderate to severe plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-03-16